A Phase 3 Randomized 3-Part Study To Investigate The Efficacy And Safety Of Dupilumab In Adult And Adolescent Patients With Eosinophilic Esophagitis

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Eosinophilic Esophagitis
  • Age: Between 18 - 99 Years
  • Gender: Male or Female

Recruitment Status

Enrolling By Invitation

For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com